Appointment of Mr Pratit Samdani as Additional Non- Executive Independent Director of the company w.e.f. April 29, 2026.

RPG Life Sciences Board meeting on April 29, 2026 approved multiple items including audited FY26 results, a Rs.24 dividend per share (300% on Rs.8 face value), and appointment of Dr. Pratit Samdani as an Additional Non-Executive Independent Director for 5 years. For FY26, standalone revenue grew 8.3% to Rs.70,752 lakhs, but net profit fell 37% to Rs.11,517 lakhs versus FY25 due to one-time gains in the prior year (Rs.10,018 lakhs from leasehold land sale). Excluding exceptional items, profit before tax remained flat at Rs.15,030 lakhs. The company received Rs.3,137 lakhs full and final insurance settlement for a fire incident at its Navi Mumbai API plant, recognizing net income of Rs.2,475 lakhs. Cash and cash equivalents improved significantly to Rs.15,046 lakhs on consolidated basis. Dr. Samdani is a Mumbai-based physician with over two decades in Internal Medicine and Critical Care, not related to any director or KMP.